Kamoi K, Mitsuma T, Sato H, Yokoyama M, Washiyama K, Tanaka R, Arai O, Takasu N, Yamada T
Acta Endocrinol (Copenh). 1985 Nov;110(3):373-82. doi: 10.1530/acta.0.1100373.
A 46-year-old woman had signs of thyrotoxicosis and galactorrhoea. Serum immunoreactive TSH and its alpha-subunit increased in the presence of high serum triiodothyronine (T3), thyroxine (T4), and free T4 concentrations, whereas beta-subunit TSH was undetectable. Exogenous TRH failed to increase serum TSH. Serum TSH was markedly suppressed by glucocorticoid, but was increased by antithyroid drug. L-Dopa or bromocriptine partially suppressed, but nomifensine had no influence on serum TSH. Serum prolactin (Prl) was above normal and markedly increased by TRH, but depressed by bromocriptine and not suppressed by nomifensine. Plasma TRH was normal in the hyperthyroid state, but was increased by glucocorticoid and antithyroid drug. Excess thyroid hormone depressed plasma TRH concentrations. Basal serum GH levels were constantly low. Transsphenoidal removal of the tumour normalized serum hormones (T3, T4 free T4, TSH, alpha-subunit and Prl), and eradicated the clinical signs of hyperthyroidism and galactorrhoea. Histological study of the tumour tissue demonstrated both thyrotrophes and somatotrophes. A reciprocal relationship between serum TSH and T4 concentrations shifted to a higher level before but was normalized after removal of the tumour. Ten months later, the clinical signs of thyrotoxicosis and the increase in serum thyroid hormone recurred without a concomitant increase in serum TSH and its alpha-subunit. Thyroidal auto-antibodies were slightly positive, but thyrotrophin-binding inhibitor immunoglobulin (TBII) was negative. Administration of antithyroid drug produced a euthyroid state, but 3 years later, discontinuation of the treatment resulted in recurrent hyperthyroidism without suppressed plasma TRH and with no evidence of regrowth of the pituitary tumour. It is suggested that the patient initially had hyperthyroidism owing to excessive TSH secretion from the tumour caused by abnormal TRH secretion, and subsequently had hyperthyroidism owing to Graves' disease.
一名46岁女性有甲状腺毒症和溢乳的体征。在血清三碘甲状腺原氨酸(T3)、甲状腺素(T4)和游离T4浓度升高的情况下,血清免疫反应性促甲状腺激素(TSH)及其α亚基升高,而β亚基TSH检测不到。外源性促甲状腺激素释放激素(TRH)未能使血清TSH升高。糖皮质激素可显著抑制血清TSH,但抗甲状腺药物可使其升高。左旋多巴或溴隐亭可部分抑制血清TSH,但诺米芬辛对其无影响。血清催乳素(Prl)高于正常,TRH可使其显著升高,但溴隐亭可使其降低,诺米芬辛对其无抑制作用。甲状腺功能亢进状态下血浆TRH正常,但糖皮质激素和抗甲状腺药物可使其升高。甲状腺激素过多会降低血浆TRH浓度。基础血清生长激素(GH)水平持续偏低。经蝶窦切除肿瘤后血清激素(T3、T4、游离T4、TSH、α亚基和Prl)恢复正常,甲状腺毒症和溢乳的临床体征消失。肿瘤组织的组织学研究显示有促甲状腺细胞和生长激素细胞。血清TSH和T4浓度之间的相互关系在肿瘤切除前移至较高水平,但切除后恢复正常。10个月后,甲状腺毒症的临床体征和血清甲状腺激素升高再次出现,而血清TSH及其α亚基未随之升高。甲状腺自身抗体轻度阳性,但促甲状腺激素结合抑制免疫球蛋白(TBII)阴性。服用抗甲状腺药物可使甲状腺功能恢复正常,但3年后停药导致甲状腺功能亢进复发,血浆TRH未受抑制,且无垂体肿瘤复发的证据。提示该患者最初因异常TRH分泌导致肿瘤分泌过多TSH而患甲状腺功能亢进,随后因格雷夫斯病患甲状腺功能亢进。